Ohio is currently home to 3189 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AMT-260 Gene Therapy Study in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850
Recruiting
This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/27/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05721755
Recruiting
This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patients with squamous cell carcinoma of the head and neck that has spread from where it first started (primary site) to other places in the body (metastatic). Pembrolizumab is a type of immunotherapy that stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio
Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
NCT05438732
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Cleveland Clinic | Cole Eye Institute, Cleveland, Ohio
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Register for Updates
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
NCT05152524
Recruiting
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/27/2024
Locations: Mercy Health, Toledo, Ohio
Conditions: Ischemic Stroke, Neovascularization
Register for Updates
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
NCT04635111
Recruiting
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: OSU - James Comprehensive Cancer Center, Columbus, Ohio
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor
Register for Updates
Cardiac Sarcoidosis Randomized Trial
NCT03593759
Recruiting
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than sta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Cardiac Sarcoidosis, Sarcoidosis
Register for Updates
AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
NCT06710795
Recruiting
Medtronic is sponsoring and funding the AFFIX study, a prospective, post-market, multicenter, nonrandomized, single-arm, interventional clinical study. The purpose of this study is to evaluate the performance and safety of the MaxTack™ Motorized Fixation Device when used for fixation of prosthetic material to soft tissue in minimally invasive ventral hernia repair procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: The Ohio State University, Columbus, Ohio
Conditions: Ventral Hernia
Register for Updates
Cardiovascular and Metabolic Sciences Biorepository
NCT06560424
Recruiting
The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Cleveland Clinic Main Campus, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Metabolic Disease
Register for Updates
Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors
NCT06150183
Recruiting
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone and when it is used together with another antibody cancer drug (pembrolizumab) in patients with different types of cancer. Patients will receive either BNT314 alone or BNT314 combined with pembrolizumab. Phase 1 of the study consists of a dose escalation part, and a safety run-in (SRI) and expansion part: Dose escalation: In this part of the study, patients will be assigned to multiple dose levels (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Advanced Malignant Solid Tumor
Register for Updates
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of DCC-3116 with other anticancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: GIST
Register for Updates
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
NCT05590624
Recruiting
The purpose of this study is to examine the impact of Mediterranean-type diets on the metabolism of men with localized prostate cancer. The optimal diet for men with a suspected diagnosis of Prostate Cancer (PCa) is currently unknown. More specifically, the suggested benefits of low carbohydrate and low fat diets in PCa are not determined.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Prostate Cancer
Register for Updates
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
NCT03588975
Recruiting
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
11/26/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Chondral Defect, Articular Cartilage Defect, Articular Cartilage Disorder of Knee, Osteochondritis Dissecans (OCD)
Register for Updates